Quantum Cyber (QUCY) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
12 Mar, 2026Executive summary
An extraordinary shareholders' meeting is scheduled to vote on major proposals, including auditor ratification, share issuances, amendments to the Articles of Association, reverse share split, director appointments, incentive plan amendments, remuneration policy changes, and board resolution approvals.
The meeting will address a significant private placement investment, resulting in the potential issuance of over 95% of outstanding shares to a new investor, subject to shareholder approval.
The board recommends voting in favor of all proposals, which are considered critical for the company's future direction and compliance with Nasdaq requirements.
Voting matters and shareholder proposals
Proposals include ratifying Reliant CPA PC as auditor, approving share issuances for preferred shares, amending the Articles for share conversions and a name change, authorizing a reverse share split, appointing four directors, increasing shares under the incentive plan, amending the remuneration policy, and approving board resolutions related to the investment.
Shareholders will vote on increasing authorized share capital, converting preferred shares, and changing the company name to Quantum Cyber N.V.
Approval of these proposals is a condition for the final closing of the $6 million investment and related settlement agreements.
Board of directors and corporate governance
Four director nominees are proposed: David Lazar (to become CEO), Robert Liscouski, David Natan, and Avraham Ben-Tzvi, all with significant public company and industry experience.
If elected, the current board (except Lazar) and executive officers will resign, and the new board will be composed of a majority of independent directors.
New board committees will be formed, with anticipated appointments of independent directors to audit, compensation, and nomination committees.
Latest events from Quantum Cyber
- Offering up to $150M in securities to advance innovative cancer diagnostics amid high risk.QUCY
Registration Filing16 Dec 2025 - Up to 4.59 million shares and units are offered, with Maxim Group LLC as placement agent.QUCY
Registration Filing30 Nov 2025 - IPO aims to fund CRC diagnostics growth amid financial risk and Nasdaq compliance challenges.QUCY
Registration Filing29 Nov 2025 - Best-efforts offering seeks $5.33M for cancer diagnostics R&D and expansion, with high investor risk.QUCY
Registration Filing29 Nov 2025 - Offering up to $7.1M net to fund CRC diagnostics expansion, with high dilution and Nasdaq risks.QUCY
Registration Filing29 Nov 2025 - Raising up to $6M for cancer diagnostics, with high risk, dilution, and strong market potential.QUCY
Registration Filing29 Nov 2025 - Cancer diagnostics firm launches high-risk, dilutive best-efforts IPO to fund clinical and commercial growth.QUCY
Registration Filing29 Nov 2025 - Offering up to 30.8M shares/warrants to fund CRC diagnostics amid financial and Nasdaq risks.QUCY
Registration Filing29 Nov 2025 - Revenue up, losses down, and strategic focus sharpened for 2025 growth and FDA progress.QUCY
H1 202413 Jun 2025